Figure 1.

An illustration of a disease-modifying effect, whereby treatment delays disease progression

Footnote: At time point Y, the change on the clinical outcome over time is less with active treatment than placebo (or natural disease progression). At this time point, the decline on the clinical outcome with active treatment (A) was reached at time point X with placebo. The difference between X and Y is the time gained with active treatment. As an example, a 25% reduction in the progression on an outcome measure with a DMT is equivalent to delaying disease progress by 3 months over 12 months of treatment. Adapted from Dickson, et al. 2023, Journal of Prevention of Alzheimer’s Disease – https://creativecommons.org/licenses/by/4.0/.